青少年及年轻成人1型糖尿病混合闭环胰岛素输注简化餐食通知研究(SMASH):随机对照两中心交叉试验
在瑞士两所大学医院46例12-20岁1型糖尿病患者中开展两中心随机交叉非劣效性试验,比较mylife CamAPS FX系统下简化餐食通知(SMA)与碳水化合物计数(CC)的血糖控制。主要终点目标范围内时间SMA为69.9±12.4%,CC为70.7±13.0%,估计平均差异-0.6个百分点(95%CI -2.4, 1.1),证实非劣效;SMA组每日胰岛素总量更高(54.0±14.7 U vs 51.7±12.1 U,p=0.037)。
要点
- SMA组目标范围内时间69.9±12.4% vs CC组70.7±13.0%,估计平均差异-0.6个百分点(95%CI -2.4, 1.1),达非劣效。
- SMA组每日胰岛素总量54.0±14.7 U vs CC组51.7±12.1 U,p=0.037。
- 3例发生严重不良事件,均与干预无关。
核心结论
- 在青少年及年轻成人1型糖尿病患者中,使用CamAPS FX算法配合SMA的血糖控制不劣于配合CC的血糖控制。
研究设计与样本
- 两中心、随机交叉、非劣效性试验,纳入瑞士两所大学医院的46例12-20岁1型糖尿病患者。
- 入组前使用每日多次注射n=35、传感器增强泵n=4或混合闭环n=7治疗。
- 参与者接受两个3个月周期,使用mylife CamAPS FX系统(YpsoPump、Dexcom G6),以计算机生成序列随机分配顺序,比较SMA(个体化碳水化合物餐量)与CC。
- 主要终点为目标范围(3.9-10.0 mmol/l)内时间比例,非劣效性界值为5个百分点。
主要发现
- 意向性治疗分析中,目标范围内时间SMA组69.9±12.4% vs CC组70.7±13.0%,估计平均差异-0.6个百分点(95%CI -2.4, 1.1),证实非劣效。
- 低于3.9 mmol/l时间中位数(IQR)SMA组1.8(1.2-2.2)% vs CC组1.9(1.6-2.5)%,两组相似。
- 高于10.0 mmol/l时间SMA组28.2±12.6% vs CC组27.2±13.4%,两组相似。
- 每日胰岛素总量SMA组54.0±14.7 U vs CC组51.7±12.1 U,p=0.037。
- 3例参与者发生严重不良事件,均与干预无关。
关键数值与推荐
- 主要终点非劣效性界值为5个百分点。
- 目标范围定义为3.9-10.0 mmol/l。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The majority of hybrid closed-loop systems still require carbohydrate counting (CC) but the evidence for its justification remains limited. Here, we evaluated glucose control with simplified meal announcement (SMA) vs CC in youth and young adults with type 1 diabetes using the mylife CamAPS FX system. METHODS: We conducted a two-centre, randomised crossover, non-inferiority trial in two University Hospitals in Switzerland in 46 participants (aged 12-20 years) with type 1 diabetes using multiple daily injections (n=35), sensor-augmented pump (n=4) or hybrid closed-loop (n=7) therapy before enrolment. Participants underwent two 3 month periods with the mylife CamAPS FX system (YpsoPump, Dexcom G6) to compare SMA (individualised carbohydrate meal sizes) with CC, in a randomly assigned order using computer-generated sequences. The primary endpoint was the proportion of time glucose was in target range (3.9-10.0 mmol/l) with a non-inferiority margin of 5 percentage points. Secondary endpoints were other sensor glucose and insulin metrics, usability and safety endpoints. RESULTS: Forty-three participants (18 women and girls) completed the trial. In the intention-to-treat analysis, time in range (mean±SD) was 69.9±12.4% with SMA and 70.7±13.0% with CC (estimated mean difference -0.6 percentage points [95% CI -2.4, 1.1], demonstrating non-inferiority). Time <3.9 mmol/l (median [IQR] 1.8 [1.2-2.2]% vs 1.9 [1.6-2.5]%) and >10.0 mmol/l (28.2±12.6% vs 27.2±13.4%) was similar between periods. Total daily insulin dose was higher with SMA (54.0±14.7 U vs 51.7±12.1 U, p=0.037). Three participants experienced serious adverse events, none of which were intervention-related. CONCLUSIONS/INTERPRETATION: Glucose control using the CamAPS FX algorithm with SMA was non-inferior to its use with CC in youth and young adults with type 1 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT05481034. FUNDING: The study was supported by the Swiss Diabetes Foundation and by a YTCR grant from the Bangerter-Rhyner Foundation and the Swiss Academy of Medical Sciences. Dexcom and Ypsomed provided product support.
引用
- Laesser CI, Piazza C, Schorno N, et al. Simplified meal announcement study (SMASH) using hybrid closed-loop insulin delivery in youth and young adults with type 1 diabetes: a randomised controlled two-centre crossover trial. Diabetologia. 2024. PMID: 39560745. doi:10.1007/s00125-024-06319-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。